Go Pro
→ SPCX Warning - and Worst News for Stocks in 50 Years (From TradeSmith) (Ad)tc pixel Free MNPR Stock Alerts

Monopar Therapeutics (MNPR) Financials

Monopar Therapeutics logo
$104.50 +5.23 (+5.27%)
Closing price 04:00 PM Eastern
Extended Trading
$104.54 +0.05 (+0.04%)
As of 06:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Monopar Therapeutics

Annual Income Statements for Monopar Therapeutics

This table shows Monopar Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -1.19 -17 -3.23 -4.22 -13 -9.10 -11 -8.43 -16 -14
Consolidated Net Income / (Loss)		 -1.19 -17 -3.23 -4.22 -6.30 -9.10 -11 -8.40 -16 -14
Net Income / (Loss) Continuing Operations		 -1.19 -17 -3.23 -4.22 -13 -9.10 -11 -8.40 -16 -14
Total Pre-Tax Income 		-1.19 -17 -3.23 -4.22 -13 -9.10 -11 -8.40 -16 -14
Total Operating Income		 -1.19 -17 -3.33 -4.32 -6.51 -9.13 -11 -8.83 -16 -17
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 1.19 17 3.33 4.32 13 9.13 11 8.83 16 17
Selling, General & Admin Expense		 0.91 1.17 1.56 2.36 2.44 2.63 2.95 3.23 3.16 6.80
Research & Development Expense		 0.28 15 1.77 1.97 4.07 6.49 7.59 5.60 13 9.90
Total Other Income / (Expense), net		 0.01 0.05 0.10 0.10 0.20 0.02 0.02 0.43 0.58 2.99
Interest & Investment Income		 - - - - - - - 0.43 0.40 2.99
Other Income / (Expense), net		 - - - 0.00 0.12 - - 0.00 0.17 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - - - - - - 0.02 -0.00 0.00
Basic Earnings per Share		 $0.00 ($1.89) ($0.35) ($0.45) ($0.58) - ($0.83) ($3.04) ($4.11) ($1.85)
Weighted Average Basic Shares Outstanding		 0.00 8.78M 9.29M 9.32M 10.96M 12.47M 12.72M 2.76M 3.79M 7.41M
Weighted Average Diluted Shares Outstanding		 0.00 8.78M 9.29M 9.32M 10.96M -0.73 -0.83 17.45M 6.11M 6.69M
Weighted Average Basic & Diluted Shares Outstanding		 0.00 8.78M 9.29M 9.32M 10.96M -0.73 -0.83 17.45M 6.11M 6.69M

Quarterly Income Statements for Monopar Therapeutics

This table shows Monopar Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.96 -1.83 -1.62 -1.71 -1.32 -11 -2.62 -2.35 -3.50 -5.14 -3.93
Consolidated Net Income / (Loss)		 -1.95 -1.81 -1.64 -1.72 -1.30 -11 -2.62 -2.45 -3.44 -5.20 -3.89
Net Income / (Loss) Continuing Operations		 -1.95 -1.81 -1.64 -1.72 -1.30 -11 -2.62 -2.45 -3.44 -5.20 -3.89
Total Pre-Tax Income 		-1.95 -1.81 -1.64 -1.72 -1.30 -11 -2.62 -2.45 -3.44 -5.20 -3.89
Total Operating Income		 -2.07 -1.91 -1.72 -1.79 -1.57 -11 -3.22 -3.23 -4.09 -6.16 -5.23
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 2.07 1.91 1.72 1.79 1.57 11 3.22 3.23 4.09 6.16 5.23
Selling, General & Admin Expense		 0.75 0.88 0.76 0.66 0.59 1.15 1.58 1.50 1.50 2.21 1.74
Research & Development Expense		 1.32 1.04 0.97 1.13 0.98 9.92 1.64 1.73 2.59 3.94 3.49
Total Other Income / (Expense), net		 0.11 0.10 0.08 0.07 0.27 0.15 0.60 0.78 0.66 0.95 1.33
Interest & Investment Income		 0.11 - 0.08 0.07 0.10 - 0.60 0.78 0.66 0.95 1.33
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.01 - 0.00 -0.00 -0.01 - -0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.69) ($0.66) ($0.51) ($0.49) ($0.37) ($2.87) ($0.38) ($0.35) ($0.48) ($0.69) ($0.46)
Weighted Average Basic Shares Outstanding		 2.82M 2.76M 3.20M 3.50M 3.52M 3.79M 6.99M 7.00M 7.12M 7.41M 8.54M
Weighted Average Diluted Shares Outstanding		 14.87M 17.45M 17.48M 17.60M 5.28M 6.11M 6.12M 6.17M 6.68M 6.69M 6.70M
Weighted Average Basic & Diluted Shares Outstanding		 14.87M 17.45M 17.48M 17.60M 5.28M 6.11M 6.12M 6.17M 6.68M 6.69M 6.70M

Annual Cash Flow Statements for Monopar Therapeutics

This table details how cash moves in and out of Monopar Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.07 6.91 -2.89 6.32 3.52 3.57 -12 -0.92 39 16
Net Cash From Operating Activities		 -1.19 -2.63 -2.68 -3.02 -4.66 -7.32 -7.23 -7.86 -6.40 -12
Net Cash From Continuing Operating Activities		 -1.19 -2.63 -2.55 -3.02 -4.66 -7.15 -7.23 -7.86 -6.40 -12
Net Income / (Loss) Continuing Operations		 -1.19 -17 -3.23 -4.22 -6.30 -9.10 -11 -8.40 -16 -14
Consolidated Net Income / (Loss)		 -1.19 -17 -3.23 -4.22 -6.30 -9.10 -11 -8.40 -16 -14
Amortization Expense		 - - - - - - - - -0.01 -0.72
Non-Cash Adjustments To Reconcile Net Income		 0.00 14 0.53 1.01 1.20 1.47 1.64 1.90 8.70 1.83
Changes in Operating Assets and Liabilities, net		 -0.01 0.12 0.03 0.20 0.44 0.49 1.65 -1.35 0.49 0.40
Net Cash From Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00 -4.92 4.93 -14 -63
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 0.00 0.00 0.00 -4.92 4.93 -14 -63
Purchase of Investments		 - - - - - 0.00 -4.92 -7.88 -15 -87
Sale and/or Maturity of Investments		 - - - - - - 0.00 13 0.99 24
Net Cash From Financing Activities		 1.26 9.54 -0.21 9.35 8.18 11 0.03 2.03 59 92
Net Cash From Continuing Financing Activities		 1.26 9.54 -0.21 9.35 8.18 11 0.03 2.03 59 92
Repurchase of Common Equity		 - - - -0.97 - - - - 0.00 -35
Issuance of Debt		 - - - 0.00 - - - - 55 127
Issuance of Common Equity		 0.00 4.71 0.00 10 - 11 0.11 2.07 4.20 0.00
Other Financing Activities, net		 0.00 4.83 0.00 0.10 8.18 -0.05 -0.08 -0.05 -0.10 -0.57
Effect of Exchange Rate Changes		 - 0.00 -0.00 - 0.00 0.00 -0.00 -0.02 0.00 0.10

Quarterly Cash Flow Statements for Monopar Therapeutics

This table details how cash moves in and out of Monopar Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.70 1.75 0.54 -1.69 -0.10 40 -6.10 -0.21 88 -66 -9.29
Net Cash From Operating Activities		 -1.94 -1.55 -1.66 -1.68 -1.07 -2.00 -5.66 -1.08 -2.09 -3.37 -3.47
Net Cash From Continuing Operating Activities		 -1.94 -1.55 -1.66 -1.68 -1.07 -2.00 -5.66 -1.08 -2.09 -3.37 -3.47
Net Income / (Loss) Continuing Operations		 -1.95 -1.81 -1.64 -1.72 -1.30 -11 -2.62 -2.45 -3.44 -5.20 -3.89
Consolidated Net Income / (Loss)		 -1.95 -1.81 -1.64 -1.72 -1.30 -11 -2.62 -2.45 -3.44 -5.20 -3.89
Amortization Expense		 - - - - - - -0.12 - - - -0.80
Non-Cash Adjustments To Reconcile Net Income		 0.47 0.47 0.33 0.33 0.20 7.83 -1.65 1.28 1.10 1.10 1.69
Changes in Operating Assets and Liabilities, net		 -0.46 -0.21 -0.35 -0.30 0.03 1.10 -1.27 0.10 0.25 1.45 -0.47
Net Cash From Investing Activities		 -0.01 2.97 -0.98 -0.00 0.99 -14 -0.33 1.19 -2.13 -62 -5.58
Net Cash From Continuing Investing Activities		 -0.01 2.97 -0.98 -0.00 0.99 -14 -0.33 1.19 -2.13 -62 -5.58
Purchase of Investments		 -2.97 0.01 -0.98 -0.00 - -14 -1.93 -1.21 -5.73 -78 -41
Sale and/or Maturity of Investments		 2.96 2.96 0.00 - 0.99 - 1.60 2.40 3.60 16 35
Net Cash From Financing Activities		 0.25 0.33 3.18 -0.01 -0.02 56 -0.12 -0.32 92 -0.38 -0.20
Net Cash From Continuing Financing Activities		 0.25 0.33 3.18 -0.01 -0.02 56 -0.12 -0.32 92 -0.38 -0.20
Other Financing Activities, net		 -0.01 -0.01 -0.01 -0.01 -0.02 -0.07 -0.12 -0.32 -0.38 0.25 -0.20
Effect of Exchange Rate Changes		 - - -0.00 - - - -0.00 -0.00 - - -0.03

Annual Balance Sheets for Monopar Therapeutics

This table presents Monopar Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2.90 9.93 7.32 13 17 21 13 7.35 60 141
Total Current Assets		 2.10 9.13 7.25 13 17 21 13 7.33 60 140
Cash & Equivalents		 2.07 8.98 6.89 13 17 20 8.19 7.27 46 62
Short-Term Investments		 - - - - - 0.00 4.93 0.00 14 79
Other Current Assets		 - - 0.34 0.02 0.06 0.22 0.05 0.07 0.08 0.06
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.80 0.80 0.07 0.12 0.07 0.00 0.06 0.01 0.00 0.25
Other Noncurrent Operating Assets		 0.80 0.80 0.07 0.12 0.07 0.00 0.06 0.01 0.00 0.25
Total Liabilities & Shareholders' Equity		 2.90 9.93 7.32 13 17 21 13 7.35 60 141
Total Liabilities		 0.06 0.31 0.40 0.72 1.18 1.58 3.14 1.76 5.25 2.89
Total Current Liabilities		 0.06 0.31 0.40 0.72 1.18 1.58 3.13 1.76 5.25 2.74
Accounts Payable		 0.06 0.31 0.40 0.72 1.18 1.58 3.13 1.76 2.25 2.74
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.15
Other Noncurrent Operating Liabilities		 - - - - - 0.00 0.01 0.00 0.00 0.15
Commitments & Contingencies		 0.00 0.00 0.00 0.00 - - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.83 9.62 6.92 13 16 19 10 5.59 55 138
Total Preferred & Common Equity		 2.83 9.62 6.92 13 16 19 10 5.59 55 138
Total Common Equity		 2.83 9.62 6.92 13 16 19 10 5.59 55 138
Common Stock		 4.70 28 29 39 48 60 62 66 131 227
Retained Earnings		 -1.87 -18 -22 -26 -32 -41 -52 -60 -76 -90
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.00 -0.01 -0.01 -0.00 0.01 -0.01 0.04 0.13

Quarterly Balance Sheets for Monopar Therapeutics

This table presents Monopar Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 8.59 8.91 7.18 6.07 55 54 144 138
Total Current Assets		 8.57 8.91 7.18 6.07 55 54 144 138
Cash & Equivalents		 5.52 7.81 6.12 6.02 40 40 128 53
Short-Term Investments		 2.98 0.99 1.00 - 15 14 16 85
Other Current Assets		 0.07 0.12 0.06 0.05 0.52 0.50 0.41 0.25
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.03 0.00 0.00 0.00 0.01 0.12 0.11 0.24
Other Noncurrent Operating Assets		 0.03 0.00 0.00 0.00 0.01 0.12 0.11 0.24
Total Liabilities & Shareholders' Equity		 8.59 8.91 7.18 6.07 55 54 144 138
Total Liabilities		 1.98 1.44 1.09 1.12 1.49 1.66 2.64 2.59
Total Current Liabilities		 1.98 1.44 1.09 1.12 1.49 1.58 2.57 2.46
Accounts Payable		 1.98 1.44 1.09 1.12 1.49 1.58 2.57 2.46
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.08 0.07 0.13
Other Noncurrent Operating Liabilities		 0.00 - - - 0.00 0.08 0.07 0.13
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.61 7.48 6.09 4.95 54 52 142 135
Total Preferred & Common Equity		 6.61 7.48 6.09 4.95 54 52 142 135
Total Common Equity		 6.61 7.48 6.09 4.95 54 52 142 135
Common Stock		 65 69 70 70 132 133 226 229
Retained Earnings		 -58 -62 -64 -65 -78 -81 -84 -93
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.00 0.01 -0.01 -0.02 0.08 0.01 0.10

Annual Metrics And Ratios for Monopar Therapeutics

This table displays calculated financial ratios and metrics derived from Monopar Therapeutics' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 9,291,421.00 9,291,420.00 11,452,177.00 12,590,612.00 12,855,735.00 14,866,400.00 - 6,682,584.00
DEI Adjusted Shares Outstanding		 0.00 0.00 1,858,284.00 1,858,284.00 2,290,435.00 2,518,122.00 2,571,147.00 2,973,280.00 - 6,682,584.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -1.74 -2.27 -5.59 -3.62 -4.09 -2.83 - -2.04
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -1,291.91% 79.94% -29.80% -47.71% -42.92% -15.44% 16.19% -81.07% -8.88%
EBIT Growth		 0.00% -1,291.91% 79.94% -29.80% -47.71% -42.92% -15.44% 16.19% -81.07% -4.47%
NOPAT Growth		 0.00% -1,291.91% 79.94% -29.80% -50.54% -40.23% -15.44% 16.19% -83.01% -3.36%
Net Income Growth		 0.00% -1,296.33% 80.50% -30.88% -49.23% -44.39% -15.52% 20.10% -85.50% 11.99%
EPS Growth		 0.00% 0.00% 81.48% -28.57% -28.89% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -119.94% -2.02% -12.58% -54.50% -56.95% 1.21% -8.71% 18.50% -90.52%
Free Cash Flow Firm Growth		 0.00% 0.00% 85.05% -40.41% -69.66% -48.19% 5.98% -31.97% -3.75% -82.92%
Invested Capital Growth		 0.00% -15.95% -95.98% -2,386.49% -78.33% -30.40% -122.34% 44.61% -208.37% 50.31%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -12.19% -3.00% -16.69% -4.83% -2.21% 10.14% -128.47% 19.44%
EBIT Q/Q Growth		 0.00% 0.00% -12.19% -3.00% -16.69% -4.83% -2.21% 10.14% -128.47% 22.75%
NOPAT Q/Q Growth		 0.00% 0.00% -12.19% -3.00% -18.93% -4.83% -2.21% 10.14% -130.91% 22.75%
Net Income Q/Q Growth		 0.00% 0.00% -12.46% -3.32% -17.12% -6.46% -2.09% 11.41% -140.73% 29.45%
EPS Q/Q Growth		 0.00% 0.00% -6.06% 0.00% -13.73% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 9.97% -5.21% -13.98% -12.12% 9.17% -3.21% -7.60% -12.67%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 22.38% -22.96% -12.45% 11.82% -10.74% -36.89% -1.45%
Invested Capital Q/Q Growth		 0.00% 0.00% 160.48% -549.39% -183.49% -28.05% -67.73% 10.89% -382.20% -21.41%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 49.20% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.39% 99.71% 96.90% 97.71% 200.63% 99.74% 99.80% 95.14% 97.47% 82.12%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -41.88% -265.93% -39.04% -43.23% -44.52% -52.57% -72.44% -107.19% -51.42% -14.22%
Cash Return on Invested Capital (CROIC)		 0.00% -1,647.80% -518.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -41.88% -265.93% -39.04% -43.23% -44.52% -52.57% -72.44% -107.19% -51.42% -14.22%
Return on Equity Simple (ROE_SIMPLE)		 -41.88% -172.10% -46.66% -33.46% -40.18% -48.06% -104.22% -150.37% -28.32% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.83 -12 -2.33 -3.03 -4.56 -6.39 -7.38 -6.18 -11 -12
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -16.92% -89.24% -11.29% -11.92% -11.67% -14.65% -18.79% -21.78% -12.67% -2.02%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -110.63% -20.56% -8.48%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -1.19 -17 -3.33 -4.32 -6.39 -9.13 -11 -8.83 -16 -17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.19 -17 -3.33 -4.32 -6.39 -9.13 -11 -8.83 -16 -17
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 3.14 0.92 0.00 12.21 4.47 2.13 3.02 0.91 2.11 3.17
Price to Tangible Book Value (P/TBV)		 3.14 0.92 0.00 12.21 4.47 2.13 3.02 0.91 2.11 3.17
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 8.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.73 -0.89 -0.96 -1.03 -1.06 -1.07 -1.15 -1.30 -1.11 -1.04
Leverage Ratio		 1.02 1.03 1.04 1.06 1.07 1.08 1.16 1.31 1.12 1.04
Compound Leverage Factor		 1.02 1.03 1.01 1.03 2.14 1.08 1.16 1.25 1.09 0.86
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 81.25 10.05 0.00 125.13 32.93 12.17 -1.37 -12.81 11.78 90.48
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 32.48 29.28 18.15 18.27 14.28 12.98 4.21 4.17 26.74 51.35
Quick Ratio		 32.13 28.80 17.25 18.25 14.22 12.85 4.19 4.13 26.71 51.33
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -12 -1.72 -2.41 -4.10 -6.07 -5.71 -7.53 -7.82 -14
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.76 0.64 0.03 -0.59 -1.05 -1.36 -3.03 -1.68 -5.18 -2.57
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.12 -0.61 -0.61 -0.46 -0.32 -1.67 1.35 -3.50 2.60
Enterprise Value (EV)		 6.82 -0.09 0.00 141 53 20 17 -2.21 56 296
Market Capitalization		 8.89 8.89 0.00 154 70 40 30 5.06 116 436
Book Value per Share		 $2.55 $1.10 $0.74 $1.36 $1.37 $1.50 $0.78 $0.38 $10.43 $20.62
Tangible Book Value per Share		 $2.55 $1.10 $0.74 $1.36 $1.37 $1.50 $0.78 $0.38 $10.43 $20.62
Total Capital		 2.83 9.62 6.92 13 16 19 10 5.59 55 138
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -2.07 -8.98 -6.89 -13 -17 -20 -13 -7.27 -60 -140
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.04 -0.16 -0.04 -0.71 -1.11 -1.36 -3.08 -1.69 -2.18 -2.67
Debt-free Net Working Capital (DFNWC)		 2.03 8.82 6.85 13 16 19 10 5.58 58 138
Net Working Capital (NWC)		 2.03 8.82 6.85 13 16 19 10 5.58 58 138
Net Nonoperating Expense (NNE)		 0.35 4.93 0.90 1.20 1.75 2.71 3.14 2.22 4.27 2.02
Net Nonoperating Obligations (NNO)		 -2.07 -8.98 -6.89 -13 -17 -20 -13 -7.27 -60 -140
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.72
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($9.45) ($1.75) ($2.25) ($2.90) ($3.65) $0.00 ($3.05) ($4.11) ($1.85)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.86M 1.86M 2.12M 2.51M 2.52M 2.54M 2.76M 3.79M 7.41M
Adjusted Diluted Earnings per Share		 $0.00 ($9.45) ($1.75) ($2.25) ($2.90) ($3.65) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.86M 1.86M 2.12M 2.51M 2.52M 2.64M 3.49M 6.11M 6.69M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($9.45) ($1.75) ($2.25) ($2.90) ($3.65) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 1.76M 1.86M 1.86M 2.19M 2.49M 0.00 3.49M 6.11M 6.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.83 -12 -2.33 -3.03 -4.56 -6.39 -7.38 -6.18 -11 -12
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -23.07% 0.00% 0.00% 0.00% 0.00% 0.00% -255.16%

Quarterly Metrics And Ratios for Monopar Therapeutics

This table displays calculated financial ratios and metrics derived from Monopar Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 14,157,941.00 14,866,400.00 17,454,925.00 17,484,175.00 17,601,827.00 - 6,112,593.00 6,115,214.00 6,169,961.00 6,682,584.00 6,692,140.00
DEI Adjusted Shares Outstanding		 2,831,588.00 2,973,280.00 3,490,985.00 3,496,835.00 3,520,365.00 - 6,112,593.00 6,115,214.00 6,169,961.00 6,682,584.00 6,692,140.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.69 -0.62 -0.46 -0.49 -0.38 - -0.43 -0.39 -0.57 -0.77 -0.59
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 14.18% 34.27% 31.75% 23.17% 32.06% -479.22% -93.88% -80.81% -191.61% 44.42% -80.31%
EBIT Growth		 14.18% 34.27% 31.75% 23.17% 32.06% -479.22% -86.95% -80.81% -191.61% 44.42% -62.18%
NOPAT Growth		 14.18% 34.27% 31.75% 23.17% 23.77% -479.22% -86.95% -80.81% -159.89% 44.42% -62.18%
Net Income Growth		 18.58% 37.37% 32.59% 22.03% 33.24% -502.32% -59.94% -43.04% -163.56% 52.40% -48.31%
EPS Growth		 0.00% 37.37% 0.00% 0.00% 0.00% -334.85% 0.00% 0.00% 0.00% 75.96% 0.00%
Operating Cash Flow Growth		 9.71% -18.75% 27.11% 20.21% 44.66% -29.27% -242.11% 35.75% -94.74% -68.64% 38.66%
Free Cash Flow Firm Growth		 -45.22% -629.03% -2,442.83% -111.05% -39.69% -58.17% 0.37% 12.97% 4.82% -62.45% 3.59%
Invested Capital Growth		 -4.26% 44.61% 51.82% 56.32% 43.02% -208.37% 27.11% -1.95% -97.33% 50.31% -118.76%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 11.26% 7.45% 9.86% -3.79% 21.53% -689.01% 69.83% -0.39% -26.55% -50.38% 2.12%
EBIT Q/Q Growth		 11.26% 7.45% 9.86% -3.79% 21.53% -689.01% 70.91% -0.39% -26.55% -50.38% 15.11%
NOPAT Q/Q Growth		 11.26% 7.45% 9.86% -3.79% 11.96% -603.20% 70.91% -0.39% -26.55% -50.38% 15.11%
Net Income Q/Q Growth		 11.19% 7.16% 9.52% -4.51% 23.96% -737.68% 75.97% 6.53% -40.11% -51.29% 25.15%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 7.69% 20.31% -7.08% -1.29% 35.98% -86.16% -183.39% 80.98% -94.04% -61.21% -3.08%
Free Cash Flow Firm Q/Q Growth		 -12.08% -96.47% 2.54% 1.66% 25.82% -122.47% 38.61% 14.10% 18.87% -279.71% 63.57%
Invested Capital Q/Q Growth		 20.01% 10.89% 21.58% 21.86% -4.36% -382.20% 81.46% -9.30% -101.99% -21.41% 18.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 94.57% 94.87% 95.23% 95.89% 92.92% 98.65% 81.47% 75.86% 83.99% 84.49% 74.50%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -99.21% -107.19% -92.67% -102.31% -112.04% -51.42% -54.27% -59.38% -26.54% -14.22% -15.86%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -99.21% -107.19% -92.67% -102.31% -112.04% -51.42% -54.27% -59.38% -26.54% -14.22% -15.86%
Return on Equity Simple (ROE_SIMPLE)		 -143.46% 0.00% -101.76% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.45 -1.34 -1.21 -1.25 -1.10 -7.75 -2.26 -2.26 -2.87 -4.31 -3.66
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.45% -4.67% -4.25% -5.35% -2.78% -9.41% -1.17% -0.63% -0.76% -0.89% -0.25%
Return On Investment Capital (ROIC_SIMPLE)		 - -23.95% -16.13% -20.56% -22.29% -14.09% -4.21% -4.34% -2.02% -3.13% -2.70%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.07 -1.91 -1.72 -1.79 -1.40 -11 -3.22 -3.23 -4.09 -6.16 -5.23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.07 -1.91 -1.72 -1.79 -1.40 -11 -3.34 -3.23 -4.09 -6.16 -6.02
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.33 0.91 1.59 2.10 4.80 2.11 4.15 4.19 3.56 3.17 2.71
Price to Tangible Book Value (P/TBV)		 1.33 0.91 1.59 2.10 4.80 2.11 4.15 4.19 3.56 3.17 2.71
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.19 -1.30 -1.25 -1.24 -1.26 -1.11 -1.04 -1.04 -1.02 -1.04 -1.02
Leverage Ratio		 1.20 1.31 1.26 1.26 1.27 1.12 1.05 1.05 1.03 1.04 1.02
Compound Leverage Factor		 1.14 1.24 1.20 1.21 1.18 1.10 0.85 0.79 0.86 0.88 0.76
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -6.73 -9.70 -4.38 -5.17 -2.07 12.05 88.48 77.76 114.81 90.73 85.07
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.32 4.17 6.21 6.59 5.41 26.74 36.92 33.94 56.10 51.35 56.04
Quick Ratio		 4.29 4.13 6.13 6.53 5.36 26.71 36.56 33.63 55.94 51.33 55.94
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.37 -2.69 -2.62 -2.58 -1.91 -4.26 -2.61 -2.24 -1.82 -6.91 -2.52
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.88 -1.68 -1.32 -1.03 -1.07 -5.18 -0.96 -1.05 -2.12 -2.57 -2.10
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.08 1.35 1.42 1.33 0.81 -3.50 0.36 -0.02 -1.04 2.60 -1.14
Enterprise Value (EV)		 0.28 -2.21 3.09 5.65 18 56 168 166 360 296 229
Market Capitalization		 8.78 5.06 12 13 24 116 223 219 504 436 367
Book Value per Share		 $0.47 $0.38 $0.43 $0.35 $0.28 $10.43 $10.15 $8.54 $22.94 $20.62 $20.23
Tangible Book Value per Share		 $0.47 $0.38 $0.43 $0.35 $0.28 $10.43 $10.15 $8.54 $22.94 $20.62 $20.23
Total Capital		 6.61 5.59 7.48 6.09 4.95 55 54 52 142 138 135
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -8.49 -7.27 -8.79 -7.12 -6.02 -60 -55 -53 -144 -140 -137
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.91 -1.69 -1.32 -1.03 -1.07 -2.18 -0.97 -1.09 -2.15 -2.67 -2.21
Debt-free Net Working Capital (DFNWC)		 6.59 5.58 7.48 6.09 4.95 58 54 52 142 138 135
Net Working Capital (NWC)		 6.59 5.58 7.48 6.09 4.95 58 54 52 142 138 135
Net Nonoperating Expense (NNE)		 0.51 0.48 0.43 0.46 0.20 3.17 0.37 0.19 0.57 0.89 0.24
Net Nonoperating Obligations (NNO)		 -8.49 -7.27 -8.79 -7.12 -6.02 -60 -55 -53 -144 -140 -137
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 -0.12 0.00 0.00 0.00 -0.80
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.70) ($3.30) ($0.50) ($0.50) ($0.37) ($2.87) ($0.38) ($0.35) ($0.48) ($0.69) ($0.46)
Adjusted Weighted Average Basic Shares Outstanding		 2.82M 552.96K 3.20M 3.50M 3.52M 3.79M 6.99M 7.00M 7.12M 7.41M 8.54M
Adjusted Diluted Earnings per Share		 $0.00 ($3.30) $0.00 $0.00 $0.00 ($2.87) $0.00 $0.00 $0.00 ($0.69) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 2.97M 3.49M 3.50M 3.52M 5.28M 6.11M 6.12M 6.17M 6.68M 6.69M 6.70M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($3.30) $0.00 $0.00 $0.00 ($2.87) $0.00 $0.00 $0.00 ($0.69) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.97M 3.49M 3.50M 3.52M 5.28M 6.11M 6.12M 6.17M 6.68M 6.69M 6.70M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.45 -1.34 -1.21 -1.25 -1.10 -7.75 -2.26 -2.26 -2.87 -4.31 -3.66
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -255.16% 0.00%

Financials Breakdown Chart

Key Financial Trends

Monopar Therapeutics (NASDAQ: MNPR) remains a cash-rich, pre-revenue biotech, but its quarterly losses and cash burn continue to define the story. The latest Q1 2026 results show a company with a large balance sheet relative to its current burn rate, but still no product revenue and persistent operating losses.

  • Very strong liquidity position: As of Q1 2026, Monopar reported $52.5 million in cash and equivalents plus $84.9 million in short-term investments, or about $137.4 million in current assets.
  • Minimal debt: Total liabilities were only $2.6 million in Q1 2026, leaving the company with a very clean balance sheet.
  • Large equity cushion: Total common equity stood at $135.4 million, which supports financial flexibility for ongoing development work.
  • Operating loss improved versus the prior quarter: Q1 2026 operating loss was $5.2 million, better than $6.2 million in Q4 2025.
  • Net loss also narrowed sequentially: Q1 2026 net loss was $3.9 million versus $5.2 million in Q4 2025.
  • Interest and investment income continues to help offset losses: Q1 2026 generated $1.3 million in interest/investment income, up from $954 thousand in Q4 2025.
  • Cash burn remains manageable for now: Operating cash outflow in Q1 2026 was $3.5 million, which is modest relative to the cash and investment balance.
  • Revenue is still zero: Monopar reported no revenue in every quarter shown, so the company is still fully dependent on financing and investment income.
  • Research spending is still the main operating cost: Q1 2026 R&D expense was $3.5 million, the largest line item and a sign the company is still in development mode.
  • Long history of losses: Over the last four years of quarterly data, Monopar has remained consistently unprofitable, with quarterly net losses generally ranging from about $1.3 million to $10.9 million.
  • Share count has risen over time: Weighted average diluted shares increased from roughly 5.3 million in Q3 2024 to about 6.7 million in Q1 2026, which can dilute future upside for existing shareholders.
  • Recent capital raises materially changed the balance sheet: Cash jumped sharply in late 2024 and 2025, indicating the business has relied on equity financing to fund operations.
  • Investing cash flows have been negative in the latest quarter: Q1 2026 showed a $5.6 million investing cash outflow, driven by purchases of investments.

Bottom line: Monopar Therapeutics is in a relatively strong funding position and has plenty of balance-sheet runway compared with its current quarterly burn. However, the company is still pre-revenue and deeply dependent on successful clinical progress and future capital efficiency. For retail investors, the key question is not near-term profitability, but whether Monopar can convert its cash into meaningful pipeline value before dilution or burn become a bigger issue.

07/09/26 11:50 PM ETAI Generated. May Contain Errors.

Monopar Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Monopar Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Monopar Therapeutics' net income appears to be on an upward trend, with a most recent value of -$13.72 million in 2025, rising from -$1.19 million in 2016. The previous period was -$15.59 million in 2024. Check out Monopar Therapeutics' forecast to explore projected trends and price targets.

Monopar Therapeutics' total operating income in 2025 was -$16.70 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $16.70 million

Over the last 9 years, Monopar Therapeutics' total revenue changed from $0.00 in 2016 to $0.00 in 2025, a change of 0.0%.

Monopar Therapeutics' total liabilities were at $2.89 million at the end of 2025, a 45.0% decrease from 2024, and a 4,380.2% increase since 2016.

In the past 9 years, Monopar Therapeutics' cash and equivalents has ranged from $2.07 million in 2016 to $61.83 million in 2025, and is currently $61.83 million as of their latest financial filing in 2025.

Over the last 9 years, Monopar Therapeutics' book value per share changed from 2.55 in 2016 to 20.62 in 2025, a change of 709.5%.


Related Companies

Financial statements for NASDAQ:MNPR last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel